Results 91 to 100 of about 20,100 (304)

The PNH French Working Group Experience: Building a Strong Network of Cytometrists

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The PNH working group was created in 2010 to initiate a workshop on testing white blood cells to share international recommendations. Methods Thirty‐five French and Belgian laboratories equipped with 2‐ or 3‐laser cytometers applied three different panels with or without FLAER reagent in 305 samples.
Orianne Wagner‐Ballon, Magali Le Garff‐Tavernier, Rémi Lestestu, Bernard Drenou, Agathe Debliquis, the PNH French Working Group «CytHem‐HPN», Chantal Fossat, Claire Loosen, Bernard Chatelain, Marie Loosveld   +9 more
wiley   +1 more source

Complement factor h-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. [PDF]

, 2014
The presence of circulating autoantibodies, primarily to complement factor H antibodies (CFH-Abs) in plasma characterizes the autoimmune form of atypical hemolytic uremic syndrome (aHUS).
Giner, T., Hofer, J., Józsi, Mihály
core   +1 more source

Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes

American Journal of Hematology, Volume 100, Issue 8, Page 1397-1407, August 2025.
Mixed autoimmune hemolytic anemia (AIHA) is a rare condition characterized by the presence of both warm and cold autoantibodies, often leading to severe, treatment‐resistant hemolysis. In this systematic review of 81 patients across 35 studies, the median age was 45 years with a notable female predominance.
Jeremy W. Jacobs, Sheharyar Raza, Landon M. Clark, Laura D. Stephens, Elizabeth S. Allen, Jennifer S. Woo, Rachel Lane Walden, Cristina A. Figueroa Villalba, Christopher A. Tormey, Caroline G. Stanek, Brian D. Adkins, Evan M. Bloch, Garrett S. Booth   +12 more
wiley   +1 more source

Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study.

Blood, 2020
The optimal duration of eculizumab treatment in patients with atypical haemolytic uremic syndrome (aHUS) remains poorly defined. We conducted a prospective national multicentric open-label study in order to assess eculizumab discontinuation in children ...
F. Fakhouri, M. Fila, A. Hummel, D. Ribes, A. Sellier-Leclerc, Simon Ville, C. Pouteil‐Noble, J. Coindre, M. Le Quintrec, E. Rondeau, O. Boyer, F. Provôt, D. Djeddi, W. Hanf, Yahsou Delmas, F. Louillet, A. Lahoche, G. Favre, V. Châtelet, Emma Allain Launay, C. Presne, A. Zaloszyc, S. Caillard, S. Bally, Q. Raimbourg, L. Tricot, C. Mousson, A. Le Thuaut, C. Loirat, V. Frémeaux-Bacchi   +29 more
semanticscholar   +1 more source

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD

Annals of Neurology, 2021
During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing
D. Wingerchuk, K. Fujihara, Jacqueline Palace, A. Berthele, M. Levy, H. Kim, I. Nakashima, C. Oreja-Guevara, Kai-Chen Wang, L. Miller, S. Shang, G. Sabatella, M. Yountz, S. Pittock   +13 more
semanticscholar   +1 more source

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Drugs - Real World Outcomes
Background and Objective The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG).
Richard J. Nowak, Ali A. Habib, Andrew J. Klink, Srikanth Muppidi, Anju Parthan, S. Chloe Sader, Alexandrina Balanean, Ajeet Gajra, James F. Howard, ELEVATE Study Group   +9 more
doaj   +1 more source

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria

European Journal of Haematology, Volume 115, Issue 2, Page 125-133, August 2025.
ABSTRACT Background Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired non‐malignant haematological disorder characterised by thrombosis risk, serious complications and debilitating symptoms in untreated patients. Objective This anchored indirect treatment comparison (ITC) evaluated efficacy data between proximal complement 3 ...
Regis Peffault de Latour, Austin Kulasekararaj, David Dingli, Koo Wilson, Piotr Wojciechowski, Zalmai Hakimi, Jameel Nazir, Barbara Czech, Peter Hillmen, Jeff Szer   +9 more
wiley   +1 more source

The first successful eculizumab rescue therapy of a kidney transplant recipient with atypical hemolytic uremic syndrome in South Korea: a case report

Korean Journal of Transplantation, 2023
Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) that can result in end-stage renal disease. Patients with aHUS often have predisposing dysfunction in the complement pathway, and continuous activation of complement ...
Eun-Ki Min, Hyun Jeong Kim, Sinyoung Kim, Minsun Jung, Jin Seok Kim, Seung Hyeok Han, Kyu Ha Huh   +6 more
doaj   +1 more source

Síndrome Hemolítico Urémico Atípico en Cuidados Intensivos: Caso Clínico de un Adulto [PDF]

, 2016
info:eu-repo/semantics ...
Agudo, I, Azevedo, L, Bento, L, Cavaco, R, Germano, N, Souto-Moura, T   +5 more
core   +1 more source

Case Report: Hematopoietic Stem Cell Transplantation to Treat Severe Acquired Aplastic Anemia in a Pediatric Kidney Transplant Recipient

Pediatric Transplantation, Volume 29, Issue 5, August 2025.
ABSTRACT Background Hematopoietic stem cell transplantation (HSCT) in solid organ transplant recipients has been reported in adults. However, data on children are scarce. We report a case of an allogeneic HSCT in a 14‐year‐old girl to treat idiopathic very severe aplastic anemia (SAA). Case Presentation The girl developed end‐stage renal disease at the
Gintarė Mierkienė, Goda Elizabeta Vaitkevičienė, Karolis Ažukaitis, Augustina Jankauskienė, Jelena Rascon   +4 more
wiley   +1 more source